Course: Development of High Dose Biologics Dosage Forms will be held on May 6, 2014 in Boston, MA - part of the Biologics Formulation & Delivery Summit.
CHI’s Inaugural Biologics Formulation and Delivery Summit will provide a forum for focused discussions on current challenges and opportunities in delivery of biotherapeutics. This 2-part summit will discuss various formulation and device-based approaches for designing physiologically relevant, patient friendly, targeted biologics products.
Part 1: Formulation Strategies for Improved Delivery of Biologics (May 5-6)
Part 2: New Technologies for Biologics Delivery and Targeting (May 6-7)
The Bioprocessing Summit
August 18-22, 2014 | Boston, MA
http://www.bioprocessingsummit.com
The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line
selection to bioproduction. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
The Bioprocessing Summit continues to grow, and now comprises 12 distinct meetings in one event, including cell
culture, purification, bioproduction, quality, formulation, and novel biotherapeutic formats. The Summit also features small-group breakout discussions, networking in the busy exhibit hall, an extensive poster display, and an array of in-depth short courses and training seminars. For the full listing of speakers at this year's Summit, please click here.
This leading bioprocess meeting is hosted in Boston each summer along the lively and cosmopolitan harbor
waterfront. Hundreds of bioprocess professionals come together each year at the Summit to share practical
solutions for today’s laboratory challenges with researchers from around the world. Please visit the website www.bioprocessingsummit.com for more information and to register.
The 2015 Bioprocessing Summit plans to unite 750+ attendees from 30+ countries for five days of inspiring presentations and solutions. The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
This leading bioprocess meeting is hosted in Boston each summer. Hundreds of bioprocess professionals come together each year at the Summit to share practical solutions for today’s bioprocess challenges with researchers from around the world.
Spanning five days, the 2015 meeting includes 12 conference programs, 8 training seminars and 10 short courses.
Kuecept Ltd was founded in 2007 by a group of experienced industrial scientists to provide customised R&D solutions and consultancy services to the pharmaceutical, biotech and health-care industries.
Today, we are one of a few contract research organisations dedicated solely to providing preformulation, formulation development and enabling drug delivery services to companies in the discovery / preclinical stages. By working exclusively in this field, we have developed a wealth of knowledge and expertise of enabling drug delivery technologies and formulation know-how in drug solubility and bioavailability enhancement and with over 600 projects completed to date on over 250 NCEs, are well placed to help resolve some of the most complex drug development issues.
Our experience covers a broad range of discovery, development & related activities supporting oral, parenteral and orally / nasally inhaled drug products.
Next Generation Recombinant Protein ManufacturingKBI Biopharma
Next Generation Processes: What Model Works Best to Manufacture Recombinant Proteins in Asia?
BioPharma Asia 2017
Suntec Convention Center. Singapore, March 22, 2017
Thomas Jung, M.S. Vice President, Business Development
KBI Biopharma Inc.
Learn more about the Valitacell fluorescent polarisation based IgG quantification assay 'ValitaTITER' and about our novel ChemStress fingerprinting assay for cell line development. For more information about our products and pricing, please contact info@valitacell.com
Combinatorial chemistry is an innovative method of synthesizing many different substances quickly and at the same time.Combinatorial chemistry contrast with the time consuming and labor intensive method of traditional chemistry where compounds are synthesized individually one at a time.
CHI’s Inaugural Biologics Formulation and Delivery Summit will provide a forum for focused discussions on current challenges and opportunities in delivery of biotherapeutics. This 2-part summit will discuss various formulation and device-based approaches for designing physiologically relevant, patient friendly, targeted biologics products.
Part 1: Formulation Strategies for Improved Delivery of Biologics (May 5-6)
Part 2: New Technologies for Biologics Delivery and Targeting (May 6-7)
The Bioprocessing Summit
August 18-22, 2014 | Boston, MA
http://www.bioprocessingsummit.com
The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line
selection to bioproduction. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
The Bioprocessing Summit continues to grow, and now comprises 12 distinct meetings in one event, including cell
culture, purification, bioproduction, quality, formulation, and novel biotherapeutic formats. The Summit also features small-group breakout discussions, networking in the busy exhibit hall, an extensive poster display, and an array of in-depth short courses and training seminars. For the full listing of speakers at this year's Summit, please click here.
This leading bioprocess meeting is hosted in Boston each summer along the lively and cosmopolitan harbor
waterfront. Hundreds of bioprocess professionals come together each year at the Summit to share practical
solutions for today’s laboratory challenges with researchers from around the world. Please visit the website www.bioprocessingsummit.com for more information and to register.
The 2015 Bioprocessing Summit plans to unite 750+ attendees from 30+ countries for five days of inspiring presentations and solutions. The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking.
This leading bioprocess meeting is hosted in Boston each summer. Hundreds of bioprocess professionals come together each year at the Summit to share practical solutions for today’s bioprocess challenges with researchers from around the world.
Spanning five days, the 2015 meeting includes 12 conference programs, 8 training seminars and 10 short courses.
Kuecept Ltd was founded in 2007 by a group of experienced industrial scientists to provide customised R&D solutions and consultancy services to the pharmaceutical, biotech and health-care industries.
Today, we are one of a few contract research organisations dedicated solely to providing preformulation, formulation development and enabling drug delivery services to companies in the discovery / preclinical stages. By working exclusively in this field, we have developed a wealth of knowledge and expertise of enabling drug delivery technologies and formulation know-how in drug solubility and bioavailability enhancement and with over 600 projects completed to date on over 250 NCEs, are well placed to help resolve some of the most complex drug development issues.
Our experience covers a broad range of discovery, development & related activities supporting oral, parenteral and orally / nasally inhaled drug products.
Next Generation Recombinant Protein ManufacturingKBI Biopharma
Next Generation Processes: What Model Works Best to Manufacture Recombinant Proteins in Asia?
BioPharma Asia 2017
Suntec Convention Center. Singapore, March 22, 2017
Thomas Jung, M.S. Vice President, Business Development
KBI Biopharma Inc.
Learn more about the Valitacell fluorescent polarisation based IgG quantification assay 'ValitaTITER' and about our novel ChemStress fingerprinting assay for cell line development. For more information about our products and pricing, please contact info@valitacell.com
Combinatorial chemistry is an innovative method of synthesizing many different substances quickly and at the same time.Combinatorial chemistry contrast with the time consuming and labor intensive method of traditional chemistry where compounds are synthesized individually one at a time.
Integrated utilization of high-throughput bioreactors & high-throughput analy...KBI Biopharma
There is a strong impetus towards rapidly advancing an increasing number of novel biotherapeutics to clinical trials. However, development of cell culture processes is labor intensive and time consuming. KBI focuses on a high throughput process development (HTPD) approach using high-throughput miniaturized bioreactors and high throughput analytics that generate growth, productivity and product quality data that match those seen with classical systems. This approach enables a significant reduction in the cell culture process development timeline and costs for investigational biopharmaceuticals to reach the clinic.
10th Anniversary Compound Libraries
VISIT THE CONFERENCE WEBSITE HERE: http://bit.ly/CompoundLibrariesSlideshare
Maximizing information in early-phase R&D for an optimal library design and target selection
We are excited to conduct the 10th annual meeting of the formerly known Compound Libraries conference! Over the last decade we have provided the pharmaceutical R&D community with a wonderful platform for exchanging knowledge and ideas about how best to optimize the qualification of drug candidates.
We have hosted almost all major pharmaceutical companies and heard dozens of case-studies relating to important and acute issues. When returning back to the programs from previous years, it is interesting to look at the timeline of changing approaches, trends and market-related developments. Our topical spectrum ranged from compound management and acquisition to collaboration frameworks, open access, library design, screening and analysis.
This year we bring you 15 case studies about the most burning issues in early-stage discovery today and offer you a valuable trend-analysis and networking with peers and colleagues from pharmaceutical companies, biotechs, CROs and academic research institutes.
Benefit from participating in discussions about the following topics:
- 10 years perspective on synthesizing and designing compound libraries
- What is the role of ligand efficiency metrics in drug discovery? Have your say in this controversial debate!
- Next generation library design - working towards better PPI and epigenetic libraries
- Exploration of bioactive and novel chemical space by application of privileged structure concept design
- Learn from Janssen’s experience with the assembly of the IMI European Lead Factory (ELF) library
- What is the real potential of macrocycles and are they the drugs of the future?
10th International Conference Compound Libraries 2014Torben Haagh
VISIT THE CONFERENCE WEBSITE HERE:
http://bit.ly/CompoundLibrariesSlideshare
Maximizing information in early-phase R&D for an optimal library design and target selection
We are excited to conduct the 10th annual meeting of the formerly known Compound Libraries conference! Over the last decade we have provided the pharmaceutical R&D community with a wonderful platform for exchanging knowledge and ideas about how best to optimize the qualification of drug candidates.
We have hosted almost all major pharmaceutical companies and heard dozens of case-studies relating to important and acute issues. When returning back to the programs from previous years, it is interesting to look at the timeline of changing approaches, trends and market-related developments. Our topical spectrum ranged from compound management and acquisition to collaboration frameworks, open access, library design, screening and analysis.
This year we bring you 15 case studies about the most burning issues in early-stage discovery today and offer you a valuable trend-analysis and networking with peers and colleagues from pharmaceutical companies, biotechs, CROs and academic research institutes.
Don’t miss our 10th anniversary and join us in Berlin to take part at our legacy conference!
Benefit from participating in discussions about the following topics:
-10 years perspective on synthesizing and designing compound libraries
-What is the role of ligand efficiency metrics in drug discovery? Have your say in this controversial debate!
-Next generation library design - working towards better PPI and epigenetic libraries
-Exploration of bioactive and novel chemical space by application of privileged structure concept design
-Learn from Janssen’s experience with the assembly of the IMI European Lead Factory (ELF) library
-What is the real potential of macrocycles and are they the drugs of the future?
Similar to Course: Development of High-Dose Biologics Dosage Forms (20)
CHI's Next Generation Dx Summit 2022 | August 22-24, 2022 | Washington, D.C.James Prudhomme
Advancing Diagnostics Together
We are proud to host Cambridge Healthtech Institute's Fourteenth Annual Next Generation Dx Summit which will take place in-person at the Grand Hyatt Washington, D.C. on August 22-24. The Next Generation Dx Summit is the nexus for key opinion leaders across the world to share recent progress in diagnostic advancement and technology innovation. The event provides a valuable window on how point-of-care, infectious disease, liquid biopsy and companion diagnostics are changing the standard of care. Now in its fourteenth year, the Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important topics for the industry.
CHI's Targeting Stromal Cells in Cancer and Inflammatory Diseases Conference ...James Prudhomme
This virtual meeting will highlight cutting-edge science and provide insight into recent developments towards therapeutic stromal cell targeting in cancer and chronic inflammatory diseases. View full details and register: https://www.healthtech.com/stroma-conference
CHI's Next Generation Dx Summit | August 25-27, 2020 | Washington, DCJames Prudhomme
Next Generation Dx Summit brings together more than 800 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its twelfth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
CHI's 10th Annual Next Generation Dx Summit, August 20-24, 2018, Washington, DCJames Prudhomme
Next Generation Dx Summit has grown to more than 1,000 international diagnostic professionals working in the field and offers unparalleled insight from the comprehensive programming and networking with key opinion leaders in the industry. The event is unique in the marketplace. This year the coverage spans cell- and cell-free biopsies, commercialization, reimbursement, biomarkers and companion diagnostics for immunotherapy, point-of-care testing, infectious disease, microfluidics and precision medicine. Now in its tenth year, Next Generation Dx Summit is a must-attend event with complete coverage of the most timely and important issues for the industry.
CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DCJames Prudhomme
Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.
Immuno-Oncology Course, organized by Healthcare Education ServicesJames Prudhomme
The Immuno-Oncology one-day course provides an overview of the rapidly evolving subject of immune-oncology. Delegates are offered a thorough understanding of the basics of tumor immunology as well as the essentials of immunotherapy and its application in cancer medicine. Examples of both how biologics work in the practice of oncology and of the challenges presented are demonstrated.
The program has been developed specifically to support the needs of the pharmaceutical, biotechnology and medical technology industry personnel. It is ideal for individuals with little understanding of the immunotherapy of cancer and those with an existing basic knowledge. Detailed presentations and discussion with Healthcare’s experienced and knowledgeable faculty enable thorough insight to this important subject area.
Introduction to Cancer: Focus on Solid Tumors Course, organized by Healthcare...James Prudhomme
Delegates attending this course will benefit from an introductory overview of the terminology and classification of cancer and the principle issues in its treatment. Commonly available anti-cancer drugs will be reviewed, including immunotherapies. The range of side-effects of cancer treatments will be studied in detail. Quality-of-life issues in terms of overall assessment and result interpretation will also be discussed.
Detailed consideration will be given to the treatment of major tumor types: breast, lung, upper gastrointestinal (GI), colorectal, melanoma, ovarian and prostate cancer.
Hematologic Cancers - An Introduction Course, organized by Healthcare Educati...James Prudhomme
This course reviews the hematological system and provides an overview on the spectrum of hematologic cancers. The expert teaching team, comprising currently practising physicians, guides course attendees through the pathophysiology of Hematologic Cancers - An Introduction such as leukemias, lymphomas and myeloma. Common treatments and management of these malignancies are discussed as well as the challenges these treatments present to patients. The issues and complications of bone marrow and stem cell transplant are also reviewed. Case studies and open discussion form an integral part of the program.
Overcome Operational Challenges in Biomarker-driven Clinical TrialsJames Prudhomme
Cambridge Healthtech Institute offers two back-to-back symposia on the operational aspects of precision medicine trials and the improvement of infrastructure to better support those trials. The 2nd Annual Managing Precision Medicine Trials Symposium (January 24-25, 2017) focuses on strategizing design for biomarker driven trials and novel clinical trial design. The Inaugural Sample, Lab and Diagnostics Services in Clinical Trials Symposium (January 25-26, 2017) focuses on clinical sample management and sourcing and diagnostics services.
Cambridge Healthtech Institute (CHI) is pleased to announce the Third Annual FAST: Functional Analysis and Screening Technologies Congress. Now in its third year, the FAST Congress brings you the latest technologies and research in cellular screening.
The Third Annual Phenotypic Drug Discovery meeting will return with new updates and case studies in phenotypic screening, high-content analysis, physiologically-relevant cellular models, chemical genomics and chemical proteomics. The rapidly evolving area of 3D cellular models will be addressed by two back-to-back meetings, with the Inaugural 3D Cell Culture: Organoid, Spheroid, and Organ-on-a-Chip Models meeting focusing on the new predictive cellular models for drug discovery and toxicity assessment. It will review the use of primary and stem cells, complex co-culture cell models, tumor spheroid models, novel organ-on-a-chip models for efficacy and safety screening, functional analysis, and compound profiling. The Third Annual Screening and Functional Analysis of 3D Models meeting will follow with case studies of phenotypic and high-content screening of complex 3D cellular systems for compound and target selection.
The 2014 Congress attracted more than 250 senior delegates, representing over 160 companies from 20 countries. With half of the attendees from big pharma and biotech and a third from academia and government, the FAST Congress offers exclusive networking opportunities with diverse international attendance. Please join our focused Screening event and learn from 60+ scientific presentations, an assortment of educational courses, 20+ exhibitors and your fellow expert delegates. We look forward to seeing you at the event.
Next Generation Dx Summit 2015 - Moving Assays to the ClinicJames Prudhomme
The Next Generation Dx Summit, entering its seventh year, brings together more than 800 diagnostics professionals from across the world, providing comprehensive programming and valuable networking opportunities. Spanning from clinical diagnostics to business strategy, this year’s expanded program encompasses predictive cancer biomarkers, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, cell-free DNA, commercialization, cancer immunotherapy, and reimbursement. With widespread coverage of all the most relevant diagnostics topics, the Next Generation Dx Summit promises to be a must-attend event to hear the latest announcements and developments in this rapidly evolving field.
Cambridge Healthtech Institute's fourth annual Clinical Trial Oversight Summit will feature four co-located conferences covering best practices and recent trends relevant to clinical research monitoring, auditing, clinical quality assurance, site management, and vendor oversight. This four-day summit will include presentations from experts, case studies, interactive breakout discussion groups, workshops, and networking opportunities. Themes throughout will include risk-based approaches to clinical trial management, implementing quality systems-based approaches to GCP compliance, ensuring reliable study data, responding to the evolving regulatory landscape, and preparing sites and clinical research partners for inspection-readiness.
Call for Posters: Functional Analysis & Screening TechnologiesJames Prudhomme
Cambridge Healthtech Institute (CHI) is accepting scientific posters from industry & academic researchers on improving the screening success of rate drugs using 3D models & phenotypic screening for display at it's second annual "FAST: Functional Analysis & Screening Technologies Congress" to be held on November 17-19, 2014. www.FASTCongress.com
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
Short Courses at CHI's Immunogenicity and Bioassay Summit 2014James Prudhomme
Cambridge Healthtech Institute (CHI) will once again offer comprehensive training at the Sixth Annual Immunogenicity and Bioassay Summit 2014. The following courses are led by well-respected professionals in the pharmaceutical industry who have much experience in helping investigators overcome their difficulties with these challenging assays and with risk assessment. Delegates will enjoy an intimate setting with their peers and instructors and have the opportunity to ask questions and exchange experiences.
Make Plans to Attend the Number 1 Immunogenicity and Bioassay Event Bringing Together Industry,
Academia and Regulatory Authorities. Featuring 8 FDA Presenters!
Course: Challenges and Opportunities in Protein and Peptide Drug DeliveryJames Prudhomme
When: May 4, 2014
Where: Seaport World Trade Center, Boston, MA
Proteins and peptides represent a significant segment of the therapeutics spectrum with many promising candidates under early development or in late-stage clinical trials. Several of these molecules are poised to make a substantial impact, especially in the under-represented or unrepresented categories such as neurological disorders and neurodegenerative diseases. A key challenge to be overcome with protein and peptide based biologics, however, is their effective delivery to the target site while achieving the optimum balance of stability, safety, bioavailability, and patient compliance. This short course will provide a broad overview of the opportunities and challenges in the development of the next generation of protein and peptide therapeutic delivery systems.
PK/PD and Immunogenicity Conferences, May 2014, Boston, MA - part of PEGSJames Prudhomme
The Safety Stream at PEGS will guide attendees through the process of developing a comprehensive immunogenicity and PK/PD strategy to ensure successful biologics. With a focus on novel constructs, high level science and expert advice will examine assay strategies, management of product immunogenicity, and modeling PK/PD to improve drug performance. Risk assessment and regulatory guidance to ensure clinical success and a competitive advantage will also be addressed.
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Richard's aventures in two entangled wonderlandsRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Slide 1: Title Slide
Extrachromosomal Inheritance
Slide 2: Introduction to Extrachromosomal Inheritance
Definition: Extrachromosomal inheritance refers to the transmission of genetic material that is not found within the nucleus.
Key Components: Involves genes located in mitochondria, chloroplasts, and plasmids.
Slide 3: Mitochondrial Inheritance
Mitochondria: Organelles responsible for energy production.
Mitochondrial DNA (mtDNA): Circular DNA molecule found in mitochondria.
Inheritance Pattern: Maternally inherited, meaning it is passed from mothers to all their offspring.
Diseases: Examples include Leber’s hereditary optic neuropathy (LHON) and mitochondrial myopathy.
Slide 4: Chloroplast Inheritance
Chloroplasts: Organelles responsible for photosynthesis in plants.
Chloroplast DNA (cpDNA): Circular DNA molecule found in chloroplasts.
Inheritance Pattern: Often maternally inherited in most plants, but can vary in some species.
Examples: Variegation in plants, where leaf color patterns are determined by chloroplast DNA.
Slide 5: Plasmid Inheritance
Plasmids: Small, circular DNA molecules found in bacteria and some eukaryotes.
Features: Can carry antibiotic resistance genes and can be transferred between cells through processes like conjugation.
Significance: Important in biotechnology for gene cloning and genetic engineering.
Slide 6: Mechanisms of Extrachromosomal Inheritance
Non-Mendelian Patterns: Do not follow Mendel’s laws of inheritance.
Cytoplasmic Segregation: During cell division, organelles like mitochondria and chloroplasts are randomly distributed to daughter cells.
Heteroplasmy: Presence of more than one type of organellar genome within a cell, leading to variation in expression.
Slide 7: Examples of Extrachromosomal Inheritance
Four O’clock Plant (Mirabilis jalapa): Shows variegated leaves due to different cpDNA in leaf cells.
Petite Mutants in Yeast: Result from mutations in mitochondrial DNA affecting respiration.
Slide 8: Importance of Extrachromosomal Inheritance
Evolution: Provides insight into the evolution of eukaryotic cells.
Medicine: Understanding mitochondrial inheritance helps in diagnosing and treating mitochondrial diseases.
Agriculture: Chloroplast inheritance can be used in plant breeding and genetic modification.
Slide 9: Recent Research and Advances
Gene Editing: Techniques like CRISPR-Cas9 are being used to edit mitochondrial and chloroplast DNA.
Therapies: Development of mitochondrial replacement therapy (MRT) for preventing mitochondrial diseases.
Slide 10: Conclusion
Summary: Extrachromosomal inheritance involves the transmission of genetic material outside the nucleus and plays a crucial role in genetics, medicine, and biotechnology.
Future Directions: Continued research and technological advancements hold promise for new treatments and applications.
Slide 11: Questions and Discussion
Invite Audience: Open the floor for any questions or further discussion on the topic.
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
A brief information about the SCOP protein database used in bioinformatics.
The Structural Classification of Proteins (SCOP) database is a comprehensive and authoritative resource for the structural and evolutionary relationships of proteins. It provides a detailed and curated classification of protein structures, grouping them into families, superfamilies, and folds based on their structural and sequence similarities.
Richard's entangled aventures in wonderlandRichard Gill
Since the loophole-free Bell experiments of 2020 and the Nobel prizes in physics of 2022, critics of Bell's work have retreated to the fortress of super-determinism. Now, super-determinism is a derogatory word - it just means "determinism". Palmer, Hance and Hossenfelder argue that quantum mechanics and determinism are not incompatible, using a sophisticated mathematical construction based on a subtle thinning of allowed states and measurements in quantum mechanics, such that what is left appears to make Bell's argument fail, without altering the empirical predictions of quantum mechanics. I think however that it is a smoke screen, and the slogan "lost in math" comes to my mind. I will discuss some other recent disproofs of Bell's theorem using the language of causality based on causal graphs. Causal thinking is also central to law and justice. I will mention surprising connections to my work on serial killer nurse cases, in particular the Dutch case of Lucia de Berk and the current UK case of Lucy Letby.
Body fluids_tonicity_dehydration_hypovolemia_hypervolemia.pptx
Course: Development of High-Dose Biologics Dosage Forms
1. Dinner Short Course: Organized by Cambridge Healthtech Institute
Development of High-Dose Biologics Dosage Forms
Tuesday, May 6, 2014 | 6:00-9:00 pm
Seaport World Trade Center, Boston, MA (Dinner will be served)
Topics to be covered:
Why are high concentration dosage forms increasingly becoming important?
What are the challenges of high doses? What factors define them?
Viscosity limitations in production and delivery
Current state of the art with devices for high-volume injections
• Current understanding of what causes high viscosity in mAbs
• Studies probing underlying molecular mechanisms
• Engineering high viscosity causing molecules
• High-throughput (HT) methods for measuring viscosity: Ensuring accuracy and precision
• HT screening tools for predicting viscosity
• Excipients for reducing viscosity
• Aggregation in high-concentration formulations
• Temperature dependence of viscosity
Fill/finish challenges
Alternate methods of producing high concentration MAb solutions
Instructors:
Christopher M. Olsen, Ph.D., Senior Scientist, CMC Analytical Chemistry, Alcon Laboratories, Inc., a
Division of Novartis
Nicholas J. Darton, Ph.D., Platform Manager, Arecor Ltd.
How to Register:
Web: http://chidb.com/register/2014/pfm/reg.asp
Call: 781-972-5400
Email: reg@healthtech.com
This course is part of the Biologics Formulation & Delivery Summit.
www.healthtech.com/biologics-delivery
